Copyright
©The Author(s) 2024.
World J Clin Oncol. Apr 24, 2024; 15(4): 540-547
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.540
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.540
Table 1 Basic characteristics
| Microsatellite instability-high, n = 2358 | Microsatellite stable, n = 19593 | |||
| Immunotherapy, n = 142 | Chemotherapy, n = 860 | Immunotherapy, n = 88 | Chemotherapy, n = 8085 | |
| Follow up duration (month) | ||||
| mean ± SD | 21.91 ± 12.23 | 19.83 ± 12.89 | 18.48 ± 11.37 | 20.61 ± 11.71 |
| Median (Range) | 22.46 (0.53-48.76) | 18.58 (0.26-48.69) | 18.88 (0.79-47.31) | 30.52 (0-49.97) |
| Age (yr) | ||||
| mean ± SD | 72.32 ± 14.70 | 62.43 ± 14.42 | 66.10 ± 15.41 | 61.53 ± 13.38 |
| Median (Range) | 77 (27-90) | 63 (21-90) | 67.5 (27-90) | 62 (19-90) |
| < 65, n (%) | 34 (23.94) | 465 (54.07) | 39 (44.32) | 4661 (57.65) |
| ≥ 65, n (%) | 108 (76.06) | 395 (45.93) | 49 (55.68) | 3424 (42.35) |
| Sex, n (%) | ||||
| Male | 52 (36.62) | 437 (50.81) | 48 (54.55) | 4466 (55.24) |
| Female | 90 (63.38) | 423 (49.19) | 40 (45.45) | 3619 (44.76) |
| Race, n (%) | ||||
| White | 9 (6.34) | 47 (5.47) | 76 (6.36) | 6356 (78.61) |
| Black | 123 (86.62) | 679 (78.95) | 8 (9.09) | 1123 (13.89) |
| Other | 9 (6.34) | 125 (14.53) | 0 | 8 (0.10) |
| Unknown | 1 (0.70) | 9 (1.05) | 4 (4.41) | 598 (7.4) |
| Charlson-Deyo Score, n (%) | ||||
| 0 | 9 (6.34) | 644 (74.88) | 65 (73.86) | 6039 (74.69) |
| 1 | 123 (86.62) | 132 (15.35) | 16 (18.18) | 1260 (15.58) |
| 2 | 9 (6.34) | 43 (5.00) | 6 (6.82) | 400 (4.95) |
| ≥ 3 | 1 (0.70) | 41 (4.77) | 1 (1.14) | 386 (4.77) |
| Tumor size, n (%) | ||||
| ≤ 20 mm | 107 (75.35) | 623 (72.44) | 61 (69.32) | 5621 (69.52) |
| > 20 mm | 35 (24.65) | 237 (27.56) | 27 (30.68) | 2464 (30.48) |
| Tumor grade, n (%) | ||||
| Well differentiated | 0 | 0 | 0 | 0 |
| Moderate differentiated | 0 | 0 | 0 | 0 |
| Poorly differentiated | 0 | 0 | 0 | 0 |
| Unknown | 142 (100.00) | 860 (100.00) | 88 (100.00) | 8085 (100.00) |
Table 2 Comparative analysis of survival outcomes
| Survival analysis | Microsatellite instability-high | Microsatellite stable | ||
| Immunotherapy vs chemotherapy | Hazard ratio (95%CI) | Adjusted hazard ratio (95%CI) | Hazard ratio (95%CI) | Adjusted hazard ratio (95%CI) |
| Overall | 0.75 (0.57-0.99) | 0.57 (0.43-0.77) | 1.05 (0.77-1.43) | 0.94 (0.69-1.29) |
| One year | 1.32 (0.92-1.92) | 1.23 (0.84-1.81) | 1.43 (0.95-2.14) | 1.37 (0.91-2.06) |
| Three year | 0.74 (0.56-0.98) | 0.62 (0.46-0.82) | 0.98 (0.72-1.34) | 0.88 (0.65-1.21) |
Table 3 Comparative analysis of survival rates
| Survival rate | Microsatellite stable | Microsatellite instability-high | ||
| Immunotherapy | Chemotherapy | Immunotherapy | Chemotherapy | |
| 1 yr (%) | 71.96 (61.14-80.25) | 76.78 (75.83-77.70) | 76.55 (68.64-82.72) | 69.91 (66.65-72.91) |
| 3 yr (%) | 48.06 (35.30-58.70) | 40.38 (39.01-41.74) | 50.96 (39.83-61.04) | 44.35 (40.38-48.24) |
Table 4 Comparative analysis of survival analysis by KRAS status
| Survival analysis | KRAS wild type | KRAS mutated type | ||
| Immunotherapy vs chemotherapy | Hazard ratio (95%CI) | Adjusted hazard ratio (95%CI) | Hazard ratio (95%CI) | Adjusted hazard ratio (95%CI) |
| Overall | 1.16 (0.86-1.56) | 1.01 (0.75-1.37) | 0.67 (0.42-1.07) | 0.70 (0.44-1.12) |
| One year | 1.28 (0.88-1.87) | 1.14 (0.78-1.68) | 1.33 (0.71-2.49) | 1.33 (0.71-2.50) |
| Three year | 1.17 (0.87-1.58) | 1.02 (0.76-1.37) | 0.66 (0.41-1.07) | 0.68 (0.42-1.09) |
- Citation: Niu CG, Zhang J, Rao AV, Joshi U, Okolo P. Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status. World J Clin Oncol 2024; 15(4): 540-547
- URL: https://www.wjgnet.com/2218-4333/full/v15/i4/540.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i4.540